Overview

• Consolidated net profit rose about 80% year-on-year to roughly Rs 48 crore and revenue grew about 22% to around Rs 217 crore, marking all-time highs for revenue, PAT and Ebitda.
• Operating income increased 47.8% to Rs 71.4 crore with the EBIT margin improving to 33% from 27.2% a year earlier.
• Growth was led by a 24% rise in the pathology segment, more than 20% expansion in completed tests to 53 million, and channel benefits from PharmEasy integration.
• The board declared a second interim dividend of Rs 7 per share, totaling about Rs 37.1 crore, with Oct. 24 set as the record date and payment due within 30 days of approval.
• A 2:1 bonus share issue was approved, shares traded up roughly 5% at Rs 1,324 after an intraday high of Rs 1,474, and all four covering analysts maintain buy ratings with a 12‑month consensus target near Rs 1,557.